New study using geneX for scaphoid non-unions shows promising results

Posted December 2010

A recent case series using geneX® in a minimally invasive technique shows promising results for the treatment of clinically challenging scaphoid non unions.

This study analysed the clinical follow up results after a minimum of 2 years in 15 patients with non unions of the scaphoid with minimal sclerosis. The patients were treated with arthroscopically assisted percutaneous internal fixation augmented by the injection of geneX to heal the fracture. Typically these types of fractures have a reported failure rate of between 25% to 45%, so innovative treatment procedures are required.

The cases were carried out by Dr Po-Jung Chu and Dr Jui-Tien Shih of the Taoyuan Armed Forces general Hospital, Taiwan.  Successful unions were confirmed by clinical examinations and standard radiography in 14 out of 15 patients (93%). The results are published in Arthroscopy: TheJournal of Arthroscopic and Related Surgery.

These results demonstrate the versatile delivery options of geneX in order to treat challenging and difficult cases

geneX® is a synthetic bone graft material with a unique bi-phasic composition manufactured through a proprietary process that confers the product with a reproducible negative surface charge. This property stimulates bone cell activity, accelerating bone formation and fusion by harnessing key proteins and directing osteoblast adhesion and proliferation for rapid osteogenesis. geneX® is fully resorbable and is completely replaced by bone.

Arthroscopically Assisted Use of Injectable Bone Graft Substitutes for Management of Scaphoid Nonunions.
Po-Jung Chu, M.D., Jui-Tien Shih, M.D. Arthroscopy. 2010 Oct 8. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/20934844